{"name":"Inventiva","slug":"inventiva","ticker":"IVA","exchange":"NASDAQ / Euronext Paris","domain":"inventivapharma.com","description":"Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.","hq":"Daix, France","founded":0,"employees":"69","ceo":"Frédéric Cren","sector":"NASH / Fibrosis / Hepatology","stockPrice":5.57,"stockChange":0.03,"stockChangePercent":0.54,"marketCap":"$1.3B","metrics":{"revenue":7898364.492300001,"revenueGrowth":-89.9,"grossMargin":99.7,"rdSpend":0,"netIncome":-413712598.46181124,"cash":116634345.8877,"dividendYield":0,"peRatio":-6.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2038-06-01","label":"lanifibranor patent cliff ($0.0B at risk)","drug":"lanifibranor","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-09-14","type":"regulatory","headline":"Inventiva Announces FDA Fast Track Designation for Lanifibranor in NASH","summary":"Inventiva announced that the FDA has granted Fast Track designation to lanifibranor for the treatment of NASH.","drugName":"lanifibranor","sentiment":"positive"},{"date":"2022-06-23","type":"earnings","headline":"Inventiva Reports First Quarter 2022 Financial Results","summary":"Inventiva reported its first quarter 2022 financial results, with a net loss of €14.1 million.","drugName":"","sentiment":"neutral"},{"date":"2021-12-16","type":"deal","headline":"Inventiva Enters into a Research Collaboration with the University of California, San Francisco","summary":"Inventiva entered into a research collaboration with the University of California, San Francisco to investigate the potential of lanifibranor in the treatment of idiopathic pulmonary fibrosis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPa2ZWQ3hZVWRINlVJbnhUSGhTRWo5VUh6dFc1QzVjUjQzR3d6YW5HQUhQZWlPWjQ1NVA0YUp3Um1hYWNXZmlhLVozYVAzanlZeFZ6U2Z1NGwxRmRuaDJjSkN2UmNJSGoxUE4wYmNrRGY1X05DV1dGZWVWdGFjY01kYzhYc1d2NWJDTU1sR3V3LXZ4R0h3WVE?oc=5","date":"2026-02-04","type":"pipeline","source":"Yahoo Finance","summary":"Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Yahoo Finance","headline":"Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQQmNBeFdfRU9DRUtha1ZFUHFDQ2VEOUdkaDRxdFhDX1VZVlBYc3pMQTU4ZDhxRDVIRUZUMHlTby1fVG9BclozcUFlQ01nbllIVHBoODBWaWxsNm9hSzV6V1h5NEJMMHRpejR6aHNOdGlLYkJJdnBvRHBvV0NJQWRUTVRWWTdTOHZDd0ZWVXdCZlVIV3hycDBHTjRXd0tHczJmQ3I4bHhHV3RHeXk2Z0UzWE9IM0VyYjduTHRfbkxFQWpnSWRQZVZLb0p2MmtIRkdlamphTFlsenY1Skd6?oc=5","date":"2025-12-17","type":"pipeline","source":"globenewswire.com","summary":"Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference - globenewswire.com","headline":"Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPa2pqSWlPYThpeE5Jd2R3Y28wQ3Bkb3RMSExzcHdKS05DZnJabnJyOElZUWRfdm93MXcyT3BSN25LQUljSjU4Y1NFYUlWMnV3X0JKaGpYNE5tZy11b0lmR0VPTElianNiaWdJSVV3YS1jdVhXVTJJbkF3cWJXY1VMRDVEYVRPSHBLaGEtODl0VmRGZw?oc=5","date":"2025-11-12","type":"pipeline","source":"Yahoo Finance","summary":"Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris - Yahoo Finance","headline":"Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOMmRVOG12M0p3VUlMUlhlQXFKUVlwQjlxVVg0RF9pbnVuaTdfM3VEY094N200b1Z1WjB5ZzZDZjhKXzFSX3FiQ1VDcWR2eTFkU05xbTlFeTQwQUdDbzdTbjVXZ2w0YW53dXlBekV0anRueEVPSjRKTC1qdTNCcjlROGdBSFI5TXY3ZDlNUWpLdlhGZW9oV0otd2FMVmR5Si05Z1RLRjlGMDV5ckRWOXZicUFzb3h4OFdudzY4YjZWYmpDc0ZVWFZYUUIwOTNBakt5Sm1kanFTUFNsZw?oc=5","date":"2025-10-09","type":"deal","source":"Investing.com","summary":"Stifel reiterates Buy rating on Inventiva stock, cites lanifibranor’s unique profile - Investing.com","headline":"Stifel reiterates Buy rating on Inventiva stock, cites lanifibranor’s unique profile","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNTWxEZEh6enVZcDM0TkNBWVBfallWSUhsMlg4OU1NUFdGLXNHd3Ytd3NxM3RUOGFuMW5ER09SNTZTX2pCeDM5VGZmd01wZ3k5NVlJMEJYWnE2X1E3NWM2LXJnWmhXN3VCWFZQTFRzM0l1dHBNU0VqOTQwSmYwLVcxeVZJdlFYWGsxOWVpdlpucWxMSFNITTl0Y0lYRTZGOE1lUGlyQnFnSWxCQWE5WE1vRnZEalZ2cGxXMHVUUDhpOW9BdkdCdHc3R2ZmNnVVb3M?oc=5","date":"2025-10-01","type":"pipeline","source":"globenewswire.com","summary":"Inventiva Appoints Andrew Obenshain as Chief Executive Officer - globenewswire.com","headline":"Inventiva Appoints Andrew Obenshain as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOUWxQa3RWVFlFcmNaZzBnUUFSdXVmMVRCMnJubTBWVk5PWlk0YjNPY1NLeVZhSHVZc0xiRldzbFZhZlI5SG1BSGpTVGh2cnNlNm9hNE5GT3QzMW1PdVo2M0xHOF9lQ2NUR29fWjdNQkgzZG55WFN5M2R1c0p5OFhjQUQ0ZTNKNTVaTy1oaDB4ekFUVGhJRmY2QmRXQkFuWkpObjZ1ajZ5a3V0UlkxMUJwUWF4dmFuNW9u?oc=5","date":"2024-07-08","type":"deal","source":"Seeking Alpha","summary":"Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement (IVA) - Seeking Alpha","headline":"Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement (IVA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE4xYUpBSGFLZXRLTVhfZWwxbV8zUlUyUVhuM3lRM1B4UHN3VEhCSU9IWjlMZmd3XzlqaHpGaHNEX0NPb2tpMXl3NzdnQWxDeDlZbTdpVTRoVXFCLTBuNEVGY0FjaTA?oc=5","date":"2024-05-11","type":"pipeline","source":"MarketBeat","summary":"Inventiva (IVA) Stock Forecast and Price Target 2026 $IVA - MarketBeat","headline":"Inventiva (IVA) Stock Forecast and Price Target 2026 $IVA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTE41UXZ6NW9JX2ZyTGRjdkZqRVlsMXZaN01tV2VGUG85ZGJ5UkctWFdGajQ4Z0dzMV9Jb29NY01tNm92dGZnSkpRUVJndXNqMzA?oc=5","date":"2024-02-12","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOVF8zeHd1QTFDTW9JTHlleGVtcFJJQVBjNWZkMDU2U0NGd2lTVDdWcFYtMUhBRDZDa05QcmZPQ1JyT1JyUTJHa3NBX0gwWU8yRnJwTTh1cXRlbDYzdnppRVk1a1ZLNjZXbEdnQkhGVlNXMGd4YlA3ZVR1cHZhSjFqWGp1NlpMSFRtLWtJ?oc=5","date":"2023-09-20","type":"pipeline","source":"Yahoo Finance","summary":"Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea - Yahoo Finance","headline":"Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in J","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE5Uei1xU1I0aWNsUzhWVHk5NU5LR0FhSjhTZjZkRlotbUh4bkJleG5YYXhLZ1NQYjVYTTJubno5blhBVXlXQjZzU00yLTdSMmVa?oc=5","date":"2021-01-20","type":"pipeline","source":"Yahoo Finance Australia","summary":"Inventiva S.A. (IVA) stock price, news, quote and history - Yahoo Finance Australia","headline":"Inventiva S.A. (IVA) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTFBnNVdDUXh2R1c1WXUtY2ozZnJ6WWFNdkItQmY3bEl1ekI2U3BiZEVvVXlNcXRzTnRJdTJrbDVpWWRBaU1vWHJneEliREdBXy1EdzU3bnByS0k?oc=5","date":"2020-09-21","type":"pipeline","source":"MarketBeat","summary":"Inventiva (IVA) Stock Price, News & Analysis $IVA - MarketBeat","headline":"Inventiva (IVA) Stock Price, News & Analysis $IVA","sentiment":"neutral"}],"patents":[{"drugName":"lanifibranor","drugSlug":"lanifibranor","patentNumber":"","type":"Patent Cliff","expiryDate":"2038-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Madrigal Pharmaceuticals","Fibrogen"],"therapeuticFocus":["NASH","Fibrosis","Hepatology"],"financials":{"source":"yahoo_finance","revenue":5237149.536900001,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":5237149.536900001},{"period":"2024-12-31","value":10745327.1114},{"period":"2023-12-31","value":20417056.091100004},{"period":"2022-12-31","value":14227803.7497}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":101685747.7449,"rdSpendHistory":[{"period":"2025-12-31","value":101685747.7449},{"period":"2024-12-31","value":106168224.384},{"period":"2023-12-31","value":128518691.69160001},{"period":"2022-12-31","value":70641355.1967}],"sgaSpend":62957943.975600004,"operatingIncome":-155237149.65690002,"operatingIncomeHistory":[{"period":"2025-12-31","value":-155237149.65690002},{"period":"2024-12-31","value":-109800233.7327},{"period":"2023-12-31","value":-119935747.75950001},{"period":"2022-12-31","value":-66421729.02510001}],"netIncome":-413712617.15340006,"netIncomeHistory":[{"period":"2025-12-31","value":-413712617.15340006},{"period":"2024-12-31","value":-215200934.75160003},{"period":"2023-12-31","value":-129002336.55180001},{"period":"2022-12-31","value":-63404205.6582}],"eps":-1.9,"epsHistory":[{"period":"2025-12-31","value":-1.9},{"period":"2024-12-31","value":-3.08},{"period":"2023-12-31","value":-2.43},{"period":"2022-12-31","value":-1.31}],"cash":116018691.6816,"cashHistory":[{"period":"2025-12-31","value":116018691.6816},{"period":"2024-12-31","value":112807243.08090001},{"period":"2023-12-31","value":31446261.7074},{"period":"2022-12-31","value":101328271.10910001}],"totalAssets":291484813.3173,"totalLiabilities":324804906.8019,"totalDebt":69928738.37370001,"equity":-33320093.484600004,"operatingCashflow":-122528037.48120001,"operatingCashflowHistory":[{"period":"2025-12-31","value":-122528037.48120001},{"period":"2024-12-31","value":-100383177.65040001},{"period":"2023-12-31","value":-95343458.02020001},{"period":"2022-12-31","value":-52485981.35040001}],"capex":-288551.4021,"capexHistory":[{"period":"2025-12-31","value":-288551.4021},{"period":"2024-12-31","value":-389018.69190000003},{"period":"2023-12-31","value":-630841.1220000001},{"period":"2022-12-31","value":-655373.8323}],"freeCashflow":-122816588.8833,"dividendsPaid":0,"buybacks":null,"employees":69,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":5.57,"previousClose":5.54,"fiftyTwoWeekHigh":7.98,"fiftyTwoWeekLow":2.85,"fiftyTwoWeekRange":"2.854 - 7.983","fiftyDayAverage":5.64,"twoHundredDayAverage":5.24,"beta":0.88,"enterpriseValue":1497371963.8147202,"forwardPE":-6.1,"priceToBook":-32.18,"priceToSales":170.92,"enterpriseToRevenue":189.58,"enterpriseToEbitda":-9.67,"pegRatio":0,"ebitda":-154786215.0771,"ebitdaMargin":0,"freeCashflow":-234476205.79505762,"operatingCashflow":-122528037.48120001,"totalDebt":269731308.62700003,"debtToEquity":0,"currentRatio":3.16,"returnOnAssets":-45.1,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":12,"targetMeanPrice":15.55,"targetHighPrice":26,"targetLowPrice":8.8,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0,"institutionHeldPercent":25.5,"sharesOutstanding":207647924,"floatShares":122208847,"sharesShort":642216,"shortRatio":1.45,"shortPercentOfFloat":0.3,"epsTrailing":-2.24,"epsForward":-0.91,"revenuePerShare":0.04,"bookValue":-0.17,"officers":[{"age":50,"name":"Mr. Andrew  Obenshain","title":"Chief Executive Officer"},{"age":63,"name":"Dr. Pierre  Broqua Ph.D.","title":"Co-Founder"},{"age":60,"name":"Mr. Jean  Volatier","title":"Executive VP Finance & Corporate Social Responsibility"},{"age":56,"name":"Dr. Martine  Zimmermann Pharm.D.","title":"Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs"},{"age":58,"name":"Mr. Jason A. Campagna M.D., Ph.D.","title":"President of Research & Development and Chief Medical Officer"},{"age":58,"name":"Mr. Axel-Sven  Malkomes","title":"Chief Financial Officer"},{"age":58,"name":"Ms. Susan  Coles","title":"Chief Legal Officer"},{"age":null,"name":"Ms. Pamela  Herbster","title":"Chief People Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://inventivapharma.com","phone":"33 3 80 44 75 00"}}